- NHS England limits access to new hep C drugs
- Japan prices Sovaldi well below US
- US Capitol Capsule: 'Breakthrough' fees? FDA urges self-control on requests
- Preview: EASL 2015, what's left to say in hepatitis C?
- Profile: Dr Reddy's CEO on mass exits, listening to parents & architecture
- PROFILE: Mundipharma's Antony Mattessich on his journey from terror expert to pharma, contrarian-style
JOB OF THE WEEK Promote your job vacancy